HC Wainwright Rates Incyte (INCY) Buy, $152 Price Target

HC Wainwright has reiterated its Buy rating on Incyte Corporation (NasdaqGS: INCY) with a price target of $152 as of October 13, 2026. This target remains unchanged from the previous assessment, signaling confidence in the company's future performance despite the current market conditions.

HC Wainwright's Call on Incyte

HC Wainwright's latest call maintains a Buy rating with a price target of $152. This target is 25.9% above the stock's recent trading price of $112.58 as of October 16, 2026. The firm sees potential for growth, indicating that the stock is undervalued at its current level.

Other Institutional Activity in Incyte

Several institutional investors hold significant positions in Incyte. Baker Bros. Advisors, LP holds 30,762,330 shares valued at about $3.48 billion, having increased its position slightly by 18,446 shares. Blackrock Inc. has reduced its stake by 945,095 shares, now owning 18,032,718 shares worth around $2.04 billion. Dodge & Cox Inc. also decreased its holdings by 295,288 shares, resulting in a total of 11,957,326 shares valued at approximately $1.35 billion. Vanguard Capital Management LLC added 94,000 shares, bringing its total to 11,024,289 shares valued at about $1.25 billion, while State Street Corporation increased its position slightly by 80,987 shares, ending with 9,722,336 shares worth around $1.10 billion.

Incyte Corporation Stock Down 10.2%

As of October 16, 2026, Incyte's shares are trading at $112.58. This price is significantly below the $152 target set by HC Wainwright, suggesting that the stock may be undervalued. The company has shown strong growth, with a revenue increase of 37.7% year-over-year, which is encouraging for investors looking for growth opportunities.

Recent Earnings

Incyte reported trailing twelve-month revenue of approximately $5.82 billion and an EPS of $7.84. The company's net margin stands at 27.7%, and it has a return on equity of 30.7%. The next earnings report is scheduled for October 27, 2026, which could provide further insights into its financial health and growth prospects.

Insider Buying and Selling at Incyte Corporation

Recent insider transactions include several sales by Pablo J. Cagnoni, an officer at Incyte. On August 12, 2026, he sold 10,803 shares at an average price of $120.04, totaling about $1.30 million. He also sold 10,801 shares on August 19 at an average price of $125.56, valued at roughly $1.36 million. Additionally, on September 15, he sold 23,218 shares, which has not been assigned a price yet but was valued at approximately $2.80 million. Patrick A. Mayes, another officer, sold 2,207 shares on August 5 at an average price of $123.99, totaling about $273,646.

Analysts Set New Price Targets

On October 13, 2026, HC Wainwright reiterated its Buy rating on Incyte with a target of $152. Other analysts have maintained their ratings as well; JP Morgan holds a Neutral rating with a target of $123, while Wells Fargo maintains an Equal-Weight rating with a target of $128. Stifel continues to support Incyte with a Buy rating and a target of $157, and RBC Capital maintains a Sector Perform rating with a target of $114.

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company based in Wilmington, DE. It focuses on discovering, developing, and commercializing therapeutics across the U.S., Europe, Canada, and Japan. The company has a strong presence in the biotechnology sector, which has been a key driver of its recent growth.

Bottom Line

Incyte's stock is currently trading below the target set by HC Wainwright, which could indicate a buying opportunity for investors. The next earnings report on October 27, 2026, will be critical for assessing the company's ongoing performance and growth potential.